86 related articles for article (PubMed ID: 8709341)
1. The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model.
Davol P; Frackelton AR
J Urol; 1996 Sep; 156(3):1174-9. PubMed ID: 8709341
[TBL] [Abstract][Full Text] [Related]
2. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
Davol PA; Bizuneh A; Frackelton AR
Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
[TBL] [Abstract][Full Text] [Related]
3. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model.
Davol P; Beitz JG; Mohler M; Ying W; Cook J; Lappi DA; Frackelton AR
Cancer; 1995 Jul; 76(1):79-85. PubMed ID: 8630880
[TBL] [Abstract][Full Text] [Related]
4. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance.
Davol PA; Frackelton AR
Prostate; 1999 Aug; 40(3):178-91. PubMed ID: 10398280
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo.
Beitz JG; Davol P; Clark JW; Kato J; Medina M; Frackelton AR; Lappi DA; Baird A; Calabresi P
Cancer Res; 1992 Jan; 52(1):227-30. PubMed ID: 1309225
[TBL] [Abstract][Full Text] [Related]
6. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor.
Lappi DA; Maher PA; Martineau D; Baird A
J Cell Physiol; 1991 Apr; 147(1):17-26. PubMed ID: 1645359
[TBL] [Abstract][Full Text] [Related]
7. Biphasic effect of the mitotoxin bFGF-saporin on bovine lens epithelial cell growth: effect of cell density and extracellular matrix.
David T; Tassin J; Lappi DA; Baird A; Courtois Y
J Cell Physiol; 1992 Dec; 153(3):483-90. PubMed ID: 1447311
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of basic FGF and heparin binding EGF conjugated with cytotoxin saporin on vascular cell cultures.
Chen C; Li J; Micko CJ; Pierce GF; Cunningham MR; Lumsden AB
J Surg Res; 1998 Feb; 75(1):35-41. PubMed ID: 9614854
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice.
Rubenstein M; Mirochnik Y; Chou P; Guinan P
J Surg Oncol; 1996 Jul; 62(3):194-200. PubMed ID: 8667627
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
14. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
16. Large-scale purification and characterization of recombinant fibroblast growth factor-saporin mitotoxin.
McDonald JR; Ong M; Shen C; Parandoosh Z; Sosnowski B; Bussell S; Houston LL
Protein Expr Purif; 1996 Aug; 8(1):97-108. PubMed ID: 8812840
[TBL] [Abstract][Full Text] [Related]
17. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
19. Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model.
Davol PA; Garza S; Frackelton AR
Cancer; 1999 Nov; 86(9):1733-41. PubMed ID: 10547546
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.
Bandyopadhyay A; Wang L; López-Casillas F; Mendoza V; Yeh IT; Sun L
Prostate; 2005 Apr; 63(1):81-90. PubMed ID: 15468171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
